Wei Jin-Rui, Ouyang Yi-Na, Tang Meng-Ting, Yuan Jia-Zhen, Wang Pei-Li, Jiang Li-He, Wu Li-Chuan
Guangxi Key Laboratory of Efficacy Study on Chinese Materia Medica, Institute of Traditional Chinese and Zhuang-Yao Ethnic Medicine Guangxi University of Chinese Medicine, Nanning 530200, Guangxi Zhuang Autonomous Region, China.
Medical School, Guangxi University, Nanning 530004, Guangxi Zhuang Autonomous Region, China.
World J Gastrointest Oncol. 2025 Jun 15;17(6):105967. doi: 10.4251/wjgo.v17.i6.105967.
Metastasis is the main reason leading to death in colorectal cancer (CRC) and about 25% of CRC patients developed metastasis when first diagnosed. Thus, unveiling biomarkers of CRC metastasis is of great significance.
To reveal biomarkers of CRC metastasis.
Weighted gene co-expression network analysis was conducted to identify metastatic biomarkers in CRC through a systematic analysis of the GSE29621 dataset. Comprehensive validation was performed subsequently using publicly available datasets from The Cancer Genome Atlas and Gene Expression Omnibus and supplemented with experimental verification in CRC cell lines. Moreover, the identified hub gene charged multivesicular body protein 7 (CHMP7) was further subjected to clinical correlation analysis Kaplan-Meier survival curves and Gene Set Enrichment Analysis to assess its prognostic significance and potential mechanistic involvement in CRC progression.
CHMP7 was identified as a key metastatic biomarker of CRC which displayed lower expression in CRC tissues, especially in CRC patients with metastasis and CRC cell lines with high metastasis potential. The expression of CHMP7 was significantly correlated with normal, metastatic tumor, pathologic stage, and lymphatic invasion ( < 0.05). CRC patients with higher expression of CHMP7 exhibited better overall survival. Besides, Gene Set Enrichment Analysis results showed that CHMP7 might be involved in metastatic related pathways.
Our results indicate that CHMP7 might be a prognostic biomarker correlated with CRC metastasis.
转移是导致结直肠癌（CRC）患者死亡的主要原因，约25%的CRC患者在首次诊断时就已发生转移。因此，揭示CRC转移的生物标志物具有重要意义。
揭示CRC转移的生物标志物。
通过对GSE29621数据集进行系统分析，采用加权基因共表达网络分析来识别CRC中的转移生物标志物。随后使用来自癌症基因组图谱和基因表达综合数据库的公开可用数据集进行全面验证，并在CRC细胞系中进行实验验证补充。此外，对鉴定出的枢纽基因多囊泡体蛋白7（CHMP7）进一步进行临床相关性分析、 Kaplan-Meier生存曲线分析和基因集富集分析，以评估其预后意义及在CRC进展中的潜在机制。
CHMP7被鉴定为CRC的关键转移生物标志物，其在CRC组织中表达较低，尤其是在发生转移的CRC患者和具有高转移潜能的CRC细胞系中。CHMP7的表达与正常组织、转移瘤、病理分期和淋巴浸润显著相关（P<0.05）。CHMP7表达较高的CRC患者总生存期较好。此外，基因集富集分析结果表明CHMP7可能参与转移相关途径。
我们的结果表明，CHMP7可能是与CRC转移相关的预后生物标志物。
